Keyphrases
Ofatumumab
100%
Humoral Immune Response
100%
COVID-19
100%
Relapsing-remitting multiple Sclerosis
100%
Messenger RNA Vaccine
100%
Median Range
33%
Response Rate
16%
Monoclonal Antibody
16%
Clinical Trial Registry
16%
Treatment Duration
16%
Serious Adverse Events
16%
2-dose
16%
Immunoglobulin G
16%
Messenger RNA (mRNA)
16%
Short Video
16%
Vaccine Response
16%
Prospective pilot Study
16%
Vaccine Dose
16%
Third Dose
16%
Anti-CD20 Therapy
16%
Anti-CD20
16%
Coronavirus Disease 2019 Vaccination
16%
RNA Vaccination
16%
Plain Language Summary
16%
Video Summarization
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ofatumumab
100%
Multiple Sclerosis
100%
RNA Vaccine
100%
Coronavirinae
100%
Messenger RNA
100%
Diseases
100%
Clinical Trial
16%
Adverse Event
16%
Monoclonal Antibody
16%
Immunoglobulin G
16%
SARS Coronavirus
16%
Neuroscience
Multiple Sclerosis
100%
Humoral Immunity
100%
Coronavirinae
100%
Coronavirus
100%
Ofatumumab
100%
Messenger RNA
100%
CD20
33%
Monoclonal Antibody
16%
Immunoglobulin G
16%
SARS Coronavirus
16%
Immunology and Microbiology
Humoral Immunity
100%
Multiple Sclerosis
100%
COVID-19
100%
Ofatumumab
100%
RNA Vaccine
100%
CD20
33%
Monoclonal Antibody
16%
Immunoglobulin G
16%
Arm
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%